IMRA News and Press, IMARA Inc. From 01/07/21

Imara (IMRA) closed in red, down 38% yesterday as investors apparently saw the company's sickle cell data lacked benefit when compared to its peers.Data showed that IMR-687 had no meaningful impact on key measures like fetal hemoglobin ((HbF)) or hemoglobin levels when taken by itse...

Gainers: Isoray (ISR) +187%.The9 (NCTY) +48%.9 Meters Biopharma (NMTR) +40%.AIkido Pharma (AIKI) +40%.Guardion Health Sciences (GHSI) +38%.TAT Technologies (TATT) +35%.Orchard Therapeutics (ORTX) +35%.Change Healthcare (CHNG) +31%.CleanSpark (CLSK) +30%.CBAK Ener...

Imara (IMRA) rises 5% in premarket after announcing results from its Phase 2a trial evaluating IMR-687 in adult patients with sickle cell disease. Overall, the data demonstrated that the treatment was well tolerated as a monotherapy and in combination with hydroxyurea ((HU))&#x...

Promising reductions in rate of VOCs/SCPCs observed in monotherapy IMR-687 treated patients vs. placebo Biomarker data from both monotherapy IMR-687 and combination IMR-687+HU groups show improvement in markers of hemolysis with variable HbF results Reductions in hsCRP a...

Preliminary data as of August 2020 from ongoing Phase 2a o pen l abel e xtension trial s howed increase s in HbF percentage and F-cell s after approximately six months of treatment Case ...

BOSTON, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin, today announced that clinical ...

BOSTON, Nov. 17, 2020 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin, today announced the appointment of ...

IMARA Inc. (IMRA) Q3 2020 Results Earnings Conference Call November 05, 2020, 08:30 AM ET Company Participants Rahul Ballal - Chief Executive Officer Michael Gray - Chief Financial and Chief Operating Officer Conference Call Participants Joseph Schwartz - SVB Leerink Yigal Nochomovitz - Citig...

Imara (IMRA): Q3 GAAP EPS of -$0.72 in-line.Cash, cash equivalents and investments of $96.1MPress Release For further details see: Imara EPS in-line

Patient Dosing Underway in Phase 2b clinical trials of IMR-687 in sickle cell disease and beta-thalassemia IMR-687 g rant ed Orphan Drug d esignation from European Commission for sickle cell disease Company to host conference...